GIKLY - Grifols to trial new immunoglobulin therapy against COVID-19

Grifols (GIKLY) announced the start of a clinical trial to evaluate the safety and efficacy of a new COVID-19 drug, containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.Based on the Grifols immunoglobulin Gamunex®-C, the treatment aims to provide immediate post-exposure protection against the virus, acting as a useful complement to the vaccine in the early phase after vaccination, a statement from the company said.According to the company, it will be a useful complement to the vaccine in the early phase after vaccination and could protect the elderly and healthcare workers as well as the immunocompromised for whom vaccination is not recommended. It will also help contain outbreaks where vaccination has not started.The clinical trial conducted in Spain involving 800 asymptomatic individuals who have tested positive for the virus will begin in February 2021, with the results expected in the spring.Dr. Oriol Mitjà, a principal researcher

For further details see:

Grifols to trial new immunoglobulin therapy against COVID-19